Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Albemarle Corp. (ALB) vs Medtronic PLC (MDT) Price & Performance

Albemarle Corp.Trade
Medtronic PLCTrade

Price performance (Past 24H)

Key statistics

Albemarle Corp. vs Medtronic PLC — how do they compare? Albemarle Corp. trades at $129.36 (market cap $15.27B), while Medtronic PLC trades at $90.68 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 7.6× Albemarle Corp.'s market cap, and Medtronic PLC pays the higher dividend (3.18%). Which is the better fit depends on your goals.

ALBMDT
Market Cap
$15.27B$116.07B
Sector
Basic MaterialsHealth
52-Week High
$215.62$105.35
52-Week Low
$72.58$73.75
Enterprise Value
$17.75B$134.82B
Dividend Yield
1.27%3.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Albemarle Corp.

Albemarle (ALB) trades at $131.21, up 0.08% on the day, showing a bullish technical trend with strong support at $129 and resistance at $133. The company reported robust Q2 2026 results, beating EPS estimates with $3.75 versus $3.20 expected, driven by improved lithium pricing and specialties growth. However, net income remains negative for 2025 at -$510.63M, and the P/E ratio is elevated at 479.11, indicating high valuation expectations. Analyst sentiment is mixed with a consensus price target of $184.50 but only 42% buy ratings.

Outlook: ALB benefits from strong lithium demand and cost controls, but faces risks from volatile lithium prices and sequential margin pressure in Q3. The stock offers growth potential if execution continues, yet high valuation and earnings inconsistency warrant caution. Near-term price action hinges on Q3 results and lithium market trends.

Medtronic PLC

Medtronic (MDT) trades at $89.41, up 2.58% on the day, reflecting positive momentum. The stock exhibits bullish technical signals with strong moving average support and a consensus analyst price target of $98.75. Fundamentally, the company reported revenue of $33.54B for 2025 with a net income margin of 13.2%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights institutional acquisitions and positive developments in medical technology platforms.

The outlook for MDT is positive, driven by earnings beats, robust cash flow, and growth in cardiac and robotic surgery segments. Key opportunities include undervaluation relative to analyst targets and dividend stability. Risks involve rising debt levels and competitive pressures in the medtech sector. The stock presents a compelling case for growth-oriented income investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Albemarle Corp.

Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.

Read more on ALB

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT